Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
236 trials
Recruiting nowPhase 2
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Recruiting nowPhase 2
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Recruiting nowPhase 2
Total Neoadjuvant Therapy in Rectal Cancer
Recruiting nowPhase 2
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
Recruiting nowPhase 2
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Recruiting nowPhase 2
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Recruiting nowPhase 2
Tislelizumab in People With Colorectal Cancer
Recruiting nowPhase 2
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Recruiting nowPhase 2
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Recruiting nowPhase 2
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Recruiting nowPhase 2
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Recruiting nowPhase 2
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
Recruiting nowEarly phase 1
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Recruiting nowPhase 2
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Recruiting nowPhase 2
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM